Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 8/20 | 0.85 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 3/20 | 0.37 |
| ▸ | PPARD | Q03181 | 2/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Candoxatril SCHEMBL1649937 | 0.92 | MME (1.00) | MMEKDM4EPPARGPPARDPPARA | |
| SCHEMBL9470376 | 0.92 | MME (0.88) | MMEKDM4EPPARGPPARDPPARA | |
| Candoxatril SCHEMBL29494166 | 0.92 | MME (1.00) | MMEKDM4EPPARGPPARDPPARA | |
| Candoxatril SCHEMBL392920 | 0.92 | MME (1.00) | MMEKDM4EPPARGPPARDPPARA | |
| Candoxatril SCHEMBL121666 | 0.92 | MME (1.00) | MMEKDM4EPPARGPPARDPPARA | |
| Candoxatril SCHEMBL5601069 | 0.92 | MME (1.00) | MMEKDM4EPPARGPPARDPPARA | |
| SCHEMBL7322664 | 0.91 | MME (0.83) | MMEKDM4EPPARGPPARDPPARA | |
| SCHEMBL7329974 | 0.91 | MME (0.83) | MMEKDM4EPPARGPPARDPPARA | |
| Candoxatril SCHEMBL14660450 | 0.90 | MME (0.95) | MMEKDM4EPPARGPPARDPPARA | |
| SCHEMBL9469895 | 0.85 | MME (0.80) | MMEKDM4EPPARGPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150098993-A1 | COMPOSITIONS, PROCESS OF PREPARATION OF SAID COMPOSITIONS AND METHOD OF TREATING INFLAMMATORY DISEASES | CELLWORKS GROUP, INC. | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150098993-A1 | COMPOSITIONS, PROCESS OF PREPARATION OF SAID COMPOSITIONS AND METHOD OF TREATING INFLAMMATORY DISEASES | TNF, C5, IL5 | MME 3204/4885KDM4E 724/4885PPARG 1381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.